EGM
CTNM

Engineers Gate Manager’s Contineum Therapeutics CTNM Stock Holding History

Engineers Gate Manager’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180K Sell
10,961
-3,995
-27% -$52.4K ﹤0.01% 1983
2026
Q1 		$195K Buy
+14,956
New +$201K ﹤0.01% 1915

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Engineers Gate Manager's CTNM Position: Q2 2026 in Review

Engineers Gate Manager reduced its Contineum Therapeutics (CTNM) stake by 27% in Q2 2026, selling an estimated $52.4K and leaving 10,961 shares worth $180K. The position accounts for ﹤0.01% of the portfolio, ranked #1983.

Engineers Gate Manager first reported a position in CTNM in Q1 2026 and has held it in 2 quarters since. The position peaked at $195K in Q1 2026. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Engineers Gate Manager held 10,961 shares of Contineum Therapeutics worth $180K as of Q2 2026.
  • Engineers Gate Manager sold 3,995 Contineum Therapeutics shares in Q2 2026, an estimated $52.4K.
  • Contineum Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1983 holding.
  • Engineers Gate Manager first reported a position in Contineum Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Engineers Gate Manager's Contineum Therapeutics position peaked at $195K in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.